A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safety/Tolerability/Efficacy of Oral Gefitinib 250 mg Versus IV Docetaxel 60 mg/m2 in Patients With Locally Advanced or Metastatic NSCL [non-small cell lung] Cancer of Adenocarcinoma Histology Previous Treated With One Platinum Base Chemotherapy.

Trial Profile

A Randomized/Open Label/Parallel Group/Multicenter/Phase IV Study to Assess Safety/Tolerability/Efficacy of Oral Gefitinib 250 mg Versus IV Docetaxel 60 mg/m2 in Patients With Locally Advanced or Metastatic NSCL [non-small cell lung] Cancer of Adenocarcinoma Histology Previous Treated With One Platinum Base Chemotherapy.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2014

At a glance

  • Drugs Docetaxel (Primary) ; Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 17 Apr 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 May 2009 Planned end date changed from 1 Jan 2009 to 1 Apr 2010 as reported by ClinicalTrials.gov.
    • 21 Nov 2007 Status changed from initiated to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top